Contents

Volume 1

Section 1: Introduction

1. **Evolution of Cardiology in India** 3
BK Goyal, SV Pagad
History *3*; Clinical Cardiology *3*; India as an Innovator *3*; Invasive Cardiology *3*; Noninterventional Cardiology *4*; Cardiology and the Future *4*

2. **Development of Interventional Cardiology: Indian Perspective** 5
MJ Gandhi
Pediatric Interventions *6*; Cardiac Electrophysiology in India *6*

Section 2: Dyslipidemia

3. **Cholesterol Management: Lessons Learned from the Recent Trials and Guidelines and their Relevance to Indian Scenario** 11
Prakash Deedwania
LdL-C as a Therapeutic Target *13*; How Low Should LdL-C go? *13*; Relevance of Lessons Learned and Recent Guidelines for the Asian Indian Patients *13*; Implementation of Guideline Directed Therapy in Clinical Practice *15*; Clinical Implications and Future Direction *16*

4. **Management of Dyslipidemia in India: How Relevant is the Western Guidelines?** 17
Subhankar Chowdhury
Relevance to Indian Populations *18*; Lipid Targets *19*; Nonstatin Drugs *19*

5. **Heart Healthy Diet: An Ever Changing Concept** 21
MS Ravi
What is an Ideal Cardioprotective Diet? *21*; Heart Healthy Diet: Evidence *21*; Concept of Beta Cell Production *22*; General Dietary Recommendations *22*; Changing Concepts of Healthy Eating *22*; How to Implement Heart Healthy Eating? *23*

6. **Newer Modalities of LDL Lowering** 24
JPS Sawhney, Saurabh Bagga, Simran Sawhney
PCSK-9 Inhibitors *25*; Antisense Oligonucleotide against Apolipoprotein B *27*; Microsomal Triglyceride Transfer Inhibitors *28*

7. **Modulation of HDL Cholesterol in Atherosclerosis** 31
SS Iyengar
Structure and Function of HdL-Cholesterol *31*; Impact on Indian Scene *33*

8. **Triglycerides: Where does it Fit in Jigsaw Puzzle?** 35
AK Pancholia
Nonfasting versus Fasting Concentrations *36*; The Role of Triglycerides in Cardiovascular Disease *36*; Triglycerides on the Rise: Should we Swap Seats on the Seesaw? *36*; Therapeutic Approaches to Hypertriglyceridemia *37*; Current Guideline Recommendations *37*

9. Non-HDL Cholesterol: Focused or Out of Focus **41**
M Somasundaram, C Elamaran
Lipoproteins *41*

10. Familial Hypercholesterolemia **45**
Harsh Wardhan, Nitin Aggarwal
Pathophysiology *45*; Clinical Presentation *46*; Diagnosis *47*; Treatment *47*

11. Safety Concerns of Currently Used Antilipidemic Agents: A Literature Review **53**
Jayanta Chakraborty, Semanti Chakraborty
Statins *53*; Rosuvastatin Wrangle *55*; Fibrates *56*; Nicotinic Acid *56*; Bile Acid Sequestrants *57*; Cholesterol Absorption Inhibitors *57*; Fish Oil *58*; Safety Concern *58*

Section 3: Hypertension

12. Hypertension in India: Trends in Prevalence, Awareness, Treatment and Control **63**
Rajeev Gupta
Recent Studies on Hypertension Prevalence in India *63*; Hypertension Awareness, Treatment and Control *65*; Implications *68*

13. Recent Hypertension Guidelines: Impact on Indian Scenario **70**
HC Kalita, Mriganka S Chaliha
Controversies Related to JNC 8 *71*; Common Meeting Points of the Major Guidelines *71*; Contradictions and Contentious Issues of the Major Guidelines *71*; Management Algorithm of Hypertension: Different Guidelines *74*; Impact of Hypertension Guidelines in Indian Scenario *76*

14. Ambulatory Blood Pressure Monitoring: Expanding Role **81**
George Koshy A, Sajan Ahmad Z
Rationale for Ambulatory Blood Pressure Monitoring *81*; ABPM—Principles and Method *81*; ABPM—Major Established Roles *82*; ABPM—Expanding Indications *85*; ABPM Targets in Hypertension Management *86*; Impediments to Expanding the Indications for ABPM *86*; ABPM—What the Guidelines Say *87*; JNC 8 (2014) *87*; ESC/ESH (2013) *87*; NICE (2011) *87*

15. Prehypertension: An Entity or a Pseudodisease **90**
Soumitra Kumar, Madhumanti Panja, Sumanta Chatterjee
Epidemiology of Prehypertension *91*; Pathophysiology of Prehypertension *92*; Evidence of Benefit with Treatment of Prehypertension *93*; Therapeutic Implications *93*

16. Central Aortic Blood Pressure: Implication in Clinical Practice **95**
Mitra KK, Sur K
Physiological Concepts *95*; Techniques to Assess Central Hemodynamics *96*; Central Aortic Pressure and Clinical Outcomes *97*

17. Choice of Antihypertensive Therapy **100**
Sukumar Ghosh, Pritam Kumar Chatterjee
2013 Updated JNC 8 Guidelines *100*; Collaborative AHA/ACC/CDC Advisory Recommendations *102*; Joint ESH and ESC Guidelines *102*; Indian Guidelines on Hypertension (IGH)-III 2013 *102*; Approach to Treatment *103*

18. Resistant Hypertension: Management Issues **108**
C Venkata S Ram, Amit A Bharadiya
Clinical Evaluation *110*; Biochemical Evaluation *111*; Noninvasive Diagnostic Testing *111*; Clinical Management *111*

19. Secondary Hypertension: An Overview **116**
Vidyut Jain, Avani Jain
Scenario *116*; When to Suspect that Patient may have Secondary Hypertension *116*; Before the Workup for Secondary Hypertension is Initiated *117*; Common Causes of Secondary Hypertension *118*

20. Hypertension in Chronic Kidney Disease: Management Dilemmas **123**
K Suresh, Harihara Sharma
Evaluation of Hypertension *123*; Dilemmas with Regard to the Choice of Drugs and Optimal Timing *125*

21. Hypertension in Pregnancy: Management **128**
NO Bansal, Mayur Jain
Pathogenesis *128*; Treatment *130*; Principles for Treatment of Mild-to-Moderate Hypertension in Pregnancy *132*; Sympathetic Nervous System Inhibition *134*; Peripherally Acting Adrenergic Receptor Antagonists *136*; Calcium Channel Antagonists *136*; Diuretics *136*; Serotonin-2 Receptor Blockers *137*; Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists *137*; Management of Hypertension Postpartum *137*; Antihypertensive Use in Breastfeeding *138*; Future Directions *138*

22. Management of Hypertension in Acute Stroke **139**
Ambuj Roy, Anunay Gupta
Benefits and Risks of Blood Pressure Lowering in Acute Ischemic Stroke *139*; Clinical Trials of BP Lowering in Ischemic Stroke *140*; Current Recommendations of BP Lowering in Acute Ischemic Stroke *141*; Current Recommendations for Blood Pressure Management in Acute Hemorrhagic Stroke *141*

23. Hypertensive Emergencies and Urgencies **143**
GR Kane, Somnath Mallakmir, Jaideep Rajebahadur
Indian Context *143*; Diagnosis *144*; History *144*; Physical Examination *144*; Management *145*

24. Hypertension and Diabetes Mellitus: An Evil Marriage **148**
Praveen Jain
Is there a Common Metabolic Pathway? *148*; Management *150*

Section 4: Coronary Artery Disease

25. Physiology of Coronary Circulation **157**
S Ramakrishnan, Deepti Siddharthan
Myocardial Oxygen Consumption and Coronary Blood Flow *157*; Autoregulation *157*; Coronary Flow vs Coronary Anatomy *159*

26. Screening for Coronary Artery Disease in Asymptomatic Individuals **162**
Satyanarayan Routray, Dipak Ranjan Das, Shisu Shankar Mishra
Resting Electrocardiogram *162*; Grouped Electrocardiogram Abnormality *163*; Adverse Effects of Electrocardiogram Screening *163*; Exercise Treadmill Testing *163*; Electron Beam Computed Tomography *164*; Coronary Computed Tomography Angiogram *164*

27. Cardiac Biomarkers in Coronary Artery Disease: What's New? **166**
Milind Phadke
Current Status of Biomarkers in CAD *166*; Newer Cardiac Biomarkers *167*

28. Noninvasive Risk Stratification in Stable Coronary Artery Disease **175**
GS Sainani, Namrata Shindekar
Prognostic Application of Myocardial Perfusion Spect *176*; Future Considerations *178*

29. Optimal Medical Management of Stable Angina **180**
BP Singh, Ravi Vishnu Prasad, Nishant Tripathy, N Kumar
Optimal Medical Therapy *180*

30. PCI in Stable Ischemic Heart Disease **190**
Saumitra Ray, Santanu Guha
Pathogenesis of SIHD *190*; PCI plus OMT versus OMT Alone *191*; PCI versus CABG *193*

31. Plaque Rupture: Newer Insights **195**
Prafulla G Kerkar, Vinay R Jaiswal, Swapnil D Mate
Plaque Rupture as the Basis of Acute Coronary Syndromes *195*; Concept of Vulnerability of Plaque (A Plaque Prone to Rupture) *196*; Imaging Techniques for Plaque Rupture and Vulnerable Plaque *197*; Noninvasive Imaging Techniques *200*; Treatment *201*; Future Perspectives *202*

32. Ischemic Conditioning: From Science to Practice **203**
K Venugopal, Sajan Ahmad Z
Concept of Myocardial Conditioning *203*; Postconditioning *204*; Some Clinically Relevant Issues in Conditioning *205*; Future Directions in Ischemic Conditioning *205*; Epilogue *205*

33. Myocardial Viability **208**
SS Ramesh, Rashmi Saligram
Assessment of Viability *209*; Combined Technology *214*; Impact of Revascularization on LV Function and Long-term Survival *214*; Clinical Implications *216*

34. ACS Risk Prediction Scores: Which to Follow? **221**
PB Jayagopal, Jain T Kallarakkal
Risk Models for ACS in Clinical Use *221*; What Score should be Used? *224*

35. Revascularization in NSTEACS: For Whom, When and How? **227**
PP Mohanan, CP Karunadas
Revascularization in Non-ST-Elevation Acute Coronary Syndrome: When? *227*; Urgent Invasive Strategy: For Whom? *227*; Early Invasive Strategy: For Whom? *227*; Delayed Invasive Strategy: For Whom? *227*; Ischemia-Guided Strategy: For Whom? *227*; Ischemia-Guided Strategy: How to Decide? *228*; Revascularization in Non-ST-Elevation Acute Coronary Syndrome: How? *229*; Percutaneous Coronary Intervention *229*; Percutaneous Coronary Intervention: Pharmacologic Therapy *229*; Urgent Coronary Artery Bypass Graft Surgery *230*; Special Groups *230*; Long-term Management *231*

36. Thrombolysis in Acute Myocardial Infarction: Present Scenario in India **232**
Satyavan Sharma, Nikhil Raut
Evolution (History) of Thrombolytic Therapy *232*; Fibrinolytic Agents *233*; Current International Recommendations *234*; Thrombolysis Scenario in India *235*

37. Prehospital Thrombolysis: How Relevant in India? **238**
M Khalilullah, Javed Ali Khan
Determinants of Death in Prehospital Phase *238*; Importance of Time in ACS *239*; Causes of Prehospital Delay *239*; Impact of Prehospital Treatment in AMI *239*; Role of Paramedics in Early Detection and Activation of CATH Lab *240*; Prehospital Thrombolysis: Clinical Data *240*; CAPTIM *240*; Prehospital Thrombolysis: Advantages and Limitations *241*; Pharmacoinvasive Approach *241*

38. Primary Angioplasty and its Challenges **247**
Vinay Kumar Bahl, Vikas Thakran
Challenges to Primary Angioplasty *248*; Therapeutic Adjuncts to Primary Angioplasty *249*

39. AMI Management and Pharmacoinvasive Therapy in STEMI **253**
Alok Majumdar, Raja Bhattacharya
STEMI Management and Pharmacoinvasive Therapy: Introduction *253*; Reperfusion Therapy *254*; Comparing Fibrinolysis and Primary PCI: Specific Focus on PHT and Transfer Patients *256*; CAPTIM *256*; DANAMI-2 and PRAGUE-2 *256*; PCI after Fibrinolytic Treatment *256*; FAST-MI *258*; Consensus Recommendation for STEMI Management, as per Consensus Statement 2013 *258*

40. Myocardial Revascularization Strategies: Year 2015 **261**
Dev B Pahlajani
Chronic Total Occlusion *263*

41. Mechanical Complications of Myocardial Infarction: Revisited **265**
Ramesh Babu Byrapaneni, Anupam Bhambhani
Ventricular Septal Rupture *265*; Left or Right Ventricular Free Wall Rupture *267*; False Aneurysm and Pseudofalse Aneurysm of LV *267*; Papillary Muscle Rupture *268*; Dynamic LVOT Obstruction after AMI *268*

42 Prevention and Management of Arrhythmia in Myocardial Infarction **271**
Trinath Kumar Mishra
Different Types of Arrhythmia and their Incidence in AMI *271*; Etiopathogenesis of Different Arrhythmia *272*; Predictors of Arrhythmia in AMI *272*; Prognosis of Arrhythmia in AMI *273*; Prevention and Management of Arrhythmia in AMI *274*

43. Unanswered Questions in the Management of STEMI **278**
Devendra V Patil, Girish R Sabnis, Prafulla G Kerkar
Pre-hospital Issues *278*; Antithrombotic Issues during Primary Angioplasty *279*; Impaired Microvascular Reperfusion and Reperfusion Injury—The 'Darker Side' of Reperfusion *280*; Role of Other Stent Systems in PPCI *282*; Approach Towards Non-infarct Related Artery Disease *282*; Management of Cardiogenic Shock *282*; Management of Arrhythmias *282*; Regenerative Cardiolgy *283*; Miscellaneous Issues *283*

44. Myocardial Infarction Following Noncardiac Surgery: Diagnostic and Management Issues **288**
Arup Dasbiswas, Arindam Maitra, Debasri Dasbiswas
Incidence *288*; Pathophysiology *288*; Prophylactic Therapy *291*

45. Acute Myocardial Infarction in the Young: Indian Perspective **297**
Kajal Ganguly, S De, A Basu, P Ghoshal, S Saha
Coronary Artery Disease in Indians—The Emerging Trend *297*; Risk Factors for Early Occurrence of CAD in Indians *298*

46. Myocardial Infarction and Stroke: How to Tackle the Deadly Duo? **301**
Saroj Mandal, D Manjunath
Risk Factors for Myocardial Infarction and Stroke *301*; Pathogenesis (Atherogenesis) *301*; Clinical Manifestations *301*; Management *303*; Management of Stroke and MI (When Occurs Simultaneously or Sequentially to Treatment MI)–Tackling the Deadly Duo *304*

47. Problems of PCI in Elderly **306**
Dhiman Kahali, Paromita Banerjee
Prevalence of Coronary Artery Disease In Elderly (US-based Data) *306*; Problems of Percutaneous Coronary Intervention in Elderly *306*; Results of Percutaneous Coronary Intervention in Elderly *306*; Access-site Complications *307*

48. Acute Coronary Syndrome in Females: An Indian Perspective **310**
Nakul Sinha
Clinical Presentation *310*; Non-invasive Testing *311*; Approach *311*; ACS in Pregnancy *313*

49. STEMI in Chronic Kidney Disease: Management Issue **316**
Anjan Lal Dutta, Ratnesh Rokade, Rajarshi Dutta
STEMI and Chronic Kidney Disease *316*; STEMI Management in Chronic Kidney Disease: Need to Overcome Therapeutic Nihilism *317*; Contrast Induced Nephropathy *317*; Antithrombotic Therapy *318*; Heparin *319*; Other Pharmacological Therapy *319*; Statins *319*

50. Myocardial Infarction with Nonobstructive Coronary Arteries **321**
K Meenakshi
Prevalence *321*; Age/Sex *322*; Race *322*; Risk Factors *322*; Type of Myocardial Infarction *322*; Angiographic Findings *322*; Diagnosis *322*; Pathogenesis *323*; Prognosis *324*; Mortality *324*; Treatment *324*

51. Microvascular Angina: Pathophysiology and Management **326**
SC Munsi, Nilesh Tawade, Vishal Vanani
Coronary Microvascular Dysfunction and Other Causes of Chest Pain without Obstructive Coronary Artery Disease *326*; Pathophysiology of Coronary Microvascular Dysfunction *327*; Coronary Microvascular Dysfunction Diagnostic Criteria *328*; Management of Microvascular Angina *328*; Refractory Angina *329*

52. Antiplatelet Therapy in Percutaneous Coronary Interventions **331**
PC Manoria, Pankaj Manoria, Piyush Manoria, RK Shrivastava, SK Parashar
Aspirin Plus Clopidogrel *331*; Clopidogrel *332*; Prasugrel *333*; Benefits in Diabetic Patients with ACS Undergoing PCI *334*; Prasugrel in Primary PCI *334*; Impact of Prasugrel on Stent Thrombosis *334*; Ticagrelor *335*; PEGASUS-TIMI 54 Study *336*; Atlantic Trial *336*; Current Issues in Antiplatelet Therapy *336*; Cangrelor *336*; Bridge Trial *337*; A Look into the Future: PAR Antagonists and Aptamers *338*

53. Intra-aortic Balloon Pump: Role Redefined **342**
MS Hiremath, Satyajeet Suryawanshi
History of IABP *342*; Pathophysiology *343*; Effects of Counterpulsation on Systemic Hemodynamics *343*; Effect of Counterpulsation on Coronary Perfusion *343*; Anatomical Considerations *343*; Technique of Insertion and Operation *343*; Indications with Evidence of Benefit *344*; Other Indications of IABP *344*; Contraindications of IABP *345*; Weaning from IABP *345*

54. Transradial Interventions: Current Status **348**
Tejas M Patel, Sanjay G Shah, Surender Deora, Samir B Pancholy
Historical Background and Global Perspective *348*; Patient Selection for Transradial Approach *349*; Radial Puncture Technique *349*; Pharmacologic Therapy *350*; Spasmolytic Therapy *350*; Antithrombotic Therapy *350*; Postprocedure Management *353*; Management of Complications *355*

55. Refractory Angina: Is there a Silver Lining? **363**
Neil Bordoloi, Ranjit Nath, Rituparna Baruah
Optimal Medical Therapy *363*; Additional Pharmacological Agents *364*; Non-pharmacological Treatments *365*

56. Connective Tissue Disorders and Atherosclerosis **369**
Dipak Sarma, Devraj Sarma, Kuntal Chakravarty
The Inflammatory Pathway *369*; The Autoimmune Pathway *371*; Management Strategies: Measures to Reduce Mortality and Morbidity *371*

57. Cardiac Rehabilitation after Myocardial Infarction **376**
Harendra Kumar, Sunil Kumar, KK Barun

58. Atherosclerosis Regression: Dream or Reality **380**
Rajan Joseph Manjuran
Low-density Lipoprotein Reduction *380*; High-density Lipoprotein Intervention *381*; Yoga Lifestyle Intervention *381*

59. Reperfusion Injury: Mechanism and Management **383**
Debdatta Bhattacharya, Peeyoosh Rai
What is Reperfusion Injury and Why is it Important? *383*; What are the Types of Myocardial Reperfusion Injury? *384*; What are the Potential Mediators of Reperfusion Injury? *385*; Which Pharmacological Strategies Attenuate Reperfusion Injury? *386*

Section 5: Cardiovascular Therapeutics

60. Vitamin D and Cardiovascular Disease **393**
SK Bhardwaj
Physiology of Vitamin D *393*; Measurement of Vitamin D *393*; Sources of Vitamin D *394*; Risk Factors *394*; Cardiovascular Diseases Associated with Vitamin D Deficiency *394*

61. CVD Risk Modulation: ARB Vis-à-Vis ACEI **397**
Dipankar Mukherjee, Malay Acharyya
Pathophysiology of Endothelial Dysfunction and its Role in Cardiovascular and Renal Dysfunction *398*; Renin-angiotensin System Blockade to Reverse Endothelial Dysfunction *398*; Improved Endothelial Function with Telmisartan *399*; Effect on GFR *399*; Effect on Proteinuria *399*; Effect on Blood Pressure *399*; Effect on Arterial Stiffness *399*; ACE-is but not ARBs, Reduce MI and CV Mortality in CAD Patients *400*; Progress Beyond HOPE and LIFE: The Ontarget Trial Programme *400*; Results of Ontarget Trial *401*; Primary Outcome and Death *401*; Discussion *401*

62. Current Status of Beta-blockers in Hypertension **403**
Asok Kumar Kar, Ayan Kar
Historical Background *403*; Adrenoceptors (ARs) and the Heart *403*; Beta-blockers in Hypertension: "Humble Beginnings to the Great Fall" *404*; Beta-blockers in End Organ Protection *405*; Newer Beta-blockers: Should we Write Them Off Too? *406*; Side Effects of Beta-blockers: Is it such a Worry? *406*

63. Iron Therapy in Heart Failure: Present Status **409**
Ajay Kumar Sinha, Pramod Kumar, Manish Gunjan, Vikas Singh
Pathophysiology *409*; Diagnosis and Clinical Presentation *409*; Therapies for Iron Deficiency HF/Current Status *410*; Clinical Implications *411*; Our Point of View *413*; Outlook *414*

64. Polypill: Role in Cardiovascular Disease Prevention **416**
(Col.) R Girish
The Epidemic of Cardiovascular Disease *416*; Prevention of Cardiovascular Disease *416*; Concept of the Polypill *417*; Rationale *417*; Composition *417*; Polypill in the Primary Prevention of CVD *417*; Polypill in the Secondary Prevention of CVD *419*; Potential Advantages and Disadvantages of the Polypill *419*; Polypills in Practice *419*

65. P2Y12 Inhibitors: Which One to Choose? **422**
Sunip Banerjee
Mechanism of Platelet Aggregation *422*; How P2Y12 Inhibitors Work *422*; Families of P2Y12 Inhibitors *423*; Important Definitions of Statistical Outcomes *425*; Evidences in Favor of Anti-P2Y12 Receptor Inclusion *425*; Major Study on P2Y12 Receptor Inhibitors *425*; Switching Between Two Anti-P2Y12 Inhibitors *425*; Implication of DAPT (Dual Antiplatelet Therapy) Beyond the Recommended Period *426*; How should we use P2Y12 Inhibitors in Post-Mi Patients? *426*; Nonadherence to P2Y12 Inhibitors *427*; What the Guidelines Say? *427*; Points to Remember when Prescribing Antipletelets *427*

66. Angiotensin Receptor and Neprilysin Inhibitors: Current Status and Future Promises **429**
Jamshed J Dalal
Renin-Angiotensin-Aldosterone System *429*; Natriuretic Peptide System *429*; Therapeutic Targeting of the NP System in Heart Failure *430*

67. Anticoagulants in the Cath Lab **435**
Soura Mookerjee
Heat PPCI: A Challenge to Bivalirudin *436*; Switching between Antithrombins *437*; Novel Anticoagulants *437*

68. Digitalis: A Forgotten Chapter **439**
SS Chatterjee, Deepesh Agarwal, Mousumi Kundu
Where did the Story come from? *440*; Digoxin's Role in Heart Failure *440*; Digoxin in Atrial Fibrillation *440*; Recent Evidences on Increased Mortality with Digoxin Use 44; Digitalis Toxicity *442*; Recommendation of use of Digoxin in Chronic Heart Failure and Atrial Fibrillation *442*

69. Current Status of Antiarrhythmic Drugs in Atrial Fibrillation **444**
Debabrata Roy, Ayan Kar
Insights from the Prefer-AF Registry *444*; Basic Atrial Electrophysiology *445*; Mechanisms of Atrial Fibrillation *446*; Novel Targets *447*

70. Thrombo-prevention: Can Newer Anticoagulant do Really Better? **450**
RK Saran, Mahim Saran, Nirdesh Jain
Background *450*; Novel Oral Anticoagulant Agents and their Pharmacological Properties *450*; Efficacy and Safety of Novel Oral Anticoagulant Agents in Landmark Trials *451*; Unsolved Issues *451*; How to Switch Intravenous Heparin/Warfarin to Novel Oral Anticoagulant Agents and Vice Versa *454*; Surgery and Procedures *454*; Should we Start Shifting of Our Patients of Nonvalvular Atrial Fibrillation who are on Warfarin to Novel Oral Anticoagulant Agents? *454*

71. Newer Antianginal Drugs **457**
Amar Patnaik
Conventional Drugs *457*; Novel Nonconventional Therapies *460*

72. Drugs and Sudden Cardiac Death **462**
Manmohan Singh, Vikas Sharma, Amitoj Singh
Mechanisms of SCD *462*; Other Causes *463*; Non-QTc Prolonging Causes of SCD *464*; Discussion *465*

Section 6: Heart Failure

73. New Biomarkers in Heart Failure **469**
Balram Bhargava, Himanshu Gupta
Biomarkers for Diagnosis of Heart Failure *469*; Natriuretic Peptides *470*; Newer Natriuretic Peptides *471*

74. Diagnostic Dilemma in Heart Failure **475**
Prabeen Kumar Rath
Heart Failure in Developing Countries *475*; Risk Factor and Progression of Heart Failure *475*; Clinical Evaluation of HF and Dilemmas Inherent in it *476*; History *476*; Physical Examination *476*; Criteria for Diagnosis of Heart Failure *477*; Investigations *479*; Acknowledgment *481*

75. Pharmacotherapy in Chronic Systolic Heart Failure: Present Status **482**
PK Asokan
Digoxin *482*; Ivabradine *482*; ACE Inhibitors *482*

76. Management of HF with Preserved Systolic Function: Current Practice [New Terminology: Heart Failure with Preserved/Normal Ejection Fraction (ESC/ACC/AHA)] **488**
Umesh C Samal, Vikas Singh
Prologue *488*; Background *488*; Established Measures in Management *488*; Present Status of Conventional Therapies *489*; Chasing a New Paradigm: How we Evolve? *489*; Pathophysiology of HFpEF and the Newer Targets of Treatment *490*; Nonpharmacological Options *493*

77. Refractory HF: Newer Avenues to Prolong Survival **495**
Mrinal Kanti Das
Device Therapy and Surgery for Heart Failure *495*; Device/Intervention Therapy of Refractory Heart Failure *496*; Cardiac Resynchronization Therapy (CRT) *498*; Implantable Cardioverter Defibrillator *498*; Coronary Revascularization Procedures *498*; Mitral Valve Interventions *498*; Cardiac Reshaping Device *498*; Left Ventricle Assist Devices *499*; Ultrafiltration *499*; Continuous Positive Airway Pressure or CPAP *499*; LV Partitioning Device *499*; Cardiac Transplantation *499*; Experimental Approaches *499*

78. Recent Novel Therapeutic Interventions in Heart Failure **502**
Harshawardhan Mardikar, Parag Admane
Recent Novel Therapeutic Interventions in Heart Failure *502*; Cardiac Resynchronization Therapy *502*; Atrial Fibrillation *503*; Right Bundle Branch Block *503*; Heart Failure with Preserved Ejection Fraction *503*; Cardiac Contractility Modulation *503*; Device-based Autonomic Modulation in Heart Failure *504*

79. Acute Decompensated Heart Failure: Where do we Stand? **507**
Prashant Bharadwaj
Pathophysiology *507*; Diagnosis *507*; Symptoms and Signs *508*; Investigations *508*; Therapy *509*; New Drugs *511*

80. Peripartum Cardiomyopathy: Revisited **512**
SC Mandal, Vishal Batra
Epidemiology *513*; Risk Factors *513*; Etiology and Pathogenesis *513*; Diagnosis *513*; Differences and Overlaps with Hypertensive Complications in Pregnancy *515*; Management of Peripartum Cardiomyopathy *516*; Prognosis *516*

81. Cardiorenal Syndrome: Have we Learnt Enough? **519**
Binoy John
Cardiorenal Syndromes Type 1 (Acute Cardiorenal Syndrome) *520*; Cardiorenal Syndrome Type 2 (Chronic Cardiorenal Syndrome) *524*; Cardiorenal Syndrome Type 3 (Acute Renocardiac Syndrome) *525*; Cardiorenal Syndrome Type 4 (Chronic Renocardiac Syndrome) *527*; Cardiorenal Syndrome Type 5 (Secondary Cardiorenal Syndrome) *529*

82. Role of Surgery in Heart Failure **531**
Alla Gopala Krishna Gokhale
Ischemic Cardiomyopathy *531*; Heart Transplantation *533*

83. Cardiac Resynchronization Therapy: Past, Present and Future **536**
Rabindra Nath Chakraborty, Arindam Pande
Past: Experience so far with Cardiac Resynchronization Therapy *536*; Cardiac Dyssynchrony *536*; Mechanical Dyssynchrony *537*; Cardiac Remodeling *537*; Patient Selection *537*; Physiologic Benefits *537*; Present: Current Status of Cardiac Resynchronization Therapy *538*; Uncertainties of Cardiac Resynchronization Therapy *538*; Future: Newer Indications for Cardiac Resynchronization Therapy *540*; Cardiac Resynchronization Therapy in NYHA Functional Class I Heart Failure *540*; Heart Failure with Narrow QRS and Coexisting Systolic Dyssynchrony *540*; Nonheart Failure Patients with Bradycardia Pacing Indications *541*; QRS Morphology and Duration: Non-left Bundle Branch Block and QRS <*150* ms *541*; Left Ventricular Lead-related Issues *542*; Multisite Left Ventricular Pacing *542*; Imaging-guided Placement of Left Ventricular Lead *543*; Nonresponders of Cardiac Resynchronization Therapy *543*; Remote Monitoring and Device-based Disease Management *543*

84. Assessment and Management of Heart Failure in Pediatric Population **546**
Debadatta Mukhopadhyay, Biswajit Bandyopadhyay, Santanu Guha
Presentation at Different Ages *546*; Single Ventricle Complexes *547*; Evaluation *547*; Biomarkers *549*; Treatment *549*; Medications *549*

85. Ventricular Assist Devices: Present Status **553**
Rony Mathew, Rupesh George, Thrideep Sagar
Historical Perspective *553*; Surgically Implanted MCS *554*; Pulsatility in Continuous Flow LVAD *554*; Selection Criteria for LVAD *555*; Contraindication for LVAD *555*; Complications *557*; Survival Rates with LVAD *557*; Percutaneous MCS *557*; Right-Sided Support *557*

Section 7: Valvular Heart Disease

86. Pathogenesis of Rheumatic Fever: As we understand it Today **561**
M Kapoor, Dhanjit Nath, Gaurav Kavi
Epidemolgy *561*; The Agent *562*; The Host *563*

87. Diagnosis and Management of Acute Rheumatic Fever **567**
Jayanta Saha, Sudhakar Singh
Diagnosing ARF: Evolution of Diagnostic Criteria *567*; Differential Diagnosis *570*; Management *570*

88. Approach to a Patient with Multivalvular Heart Disease **572**
Upendra Kaul, Parneesh Arora
Clinical Evaluation and Investigation *572*; Combination of Valvular Diseases *572*; Surgical Treatment of Multivalvular Heart Disease *573*

89. Care of Patients with Prosthetic Heart Valve **576**
Sreenivas Kumar Arramraju, Haariram Vuppaladhadiam
Types of Prosthetic Valves *576*; Selecting the Optimal Prosthesis in Individual Patient *577*; Antithrombotic Therapy *577*; Follow-up *579*; Recognition and Treatment of Complications *579*; Management of Prosthetic Valves During Pregnancy *582*

90. Rheumatic Fever in India: Future Directions **584**
IB Vijayalakshmi
Background *584*; Prevention *584*; Future Directions *584*

91. Evaluation and Management of Aortic Stenosis **590**
Arati Dave Lalchandani, Manoj Kumar Godara, Navin Mathiyalagan, Ashish Kumar Arya, Abhijeet Ranjan
Diagnosis *593*; Medical Therapy *593*; Interventional Management *593*; Choice of Intervention *593*

92. Functional Mitral Regurgitation: Reappraisal **595**
Cibu Mathew

93. Balloon Mitral Valvuloplasty **601**
CN Manjunath, Nagaraja Moorthy
Anatomic Considerations *601*; Balloon Mitral Valvuloplasty *601*; BMV in Difficult Scenarios *605*; Complications of BMV *607*; Immediate Results of BMV *609*

94. Changing Scenario of Infective Endocarditis **611**
KC Goswami, Abhinav Aggarwal, Abhinit Gupta
Epidemiology *611*; Microbiology *611*; Clinical Features *612*; Diagnosis *613*; Newer Techniques *614*; Treatment *614*; Anticoagulation and Antiplatelet Therapies *615*; Prophylaxis *615*; Surgery *616*; Special Considerations *616*

95. Low Pressure Tricuspid Regurgitation: Reappraisal **619**
Pranab Kumar Biswas, Debojyoti Sarkar
Tricuspid Valve Anatomy *619*; Hemodynamics *620*; Color Flow Mapping *621*; Vena Contracta Width *621*; Proximal Isovelocity Surface Area Method *622*; Inferior Vena Caval and Hepatic Vein Flow *622*; Echo Feature of Specific Diseases *622*; Endocarditis *623*; Tricuspid Valve Prolapse *623*; Papillary Muscle Rupture or Dysfunction and Rupture of Chordae Tendineae *623*; Congenital Heart Disease *623*; Carcinoid Heart Disease *623*; Other Causes *624*; Management *624*

96. MitraClip: Current Perspective **627**
Goutam Datta
History and Development *627*; MitraClip Procedure *627*; Indications and Patient Selection *629*; Contraindications *629*; Procedural Efficacy *629*; Hemodynamic Effects of MitraClip *629*; Complication *629*; Long-term Outcome Data *630*; High-risk Subgroups *630*; Safety *631*; Future Perspective *633*

97. Valvular Heart Diseases in Pregnancy **639**
Geetha Subramanian, Gnanavelu Ganesan, Cecily Mary Majella
Etiology of Valvular Heart Diseases in Pregnancy *639*; Hemodynamic Alterations in Pregnancy *639*; Maternal Risk Assessment of Valvular Heart Diseases during Pregnancy *640*; Evaluation of Individual Valvular Lesions in Pregnancy *642*; Mitral and Aortic Insufficiency *643*; Tricuspid Regurgitation *643*; Pulmonic Stenosis and Insufficiency *643*; Coarctation of the Aorta with Bicuspid Aortic Valve in Pregnancy *643*; Prosthetic Valve of Choice for a Woman of Child Bearing Age *643*; Oral Anticoagulants *644*; Unfractionated Heparin *644*; Low Molecular Weight Heparin *644*; Current Data on Prosthetic Valve Thrombosis *644*; Comparison of Anticoagulation Options *644*; Use of Other Cardiac Drugs in Valvular Heart Diseases in Pregnancy *644*; Choice of Contraception in Women with Valvular Heart Diseases *645*; Mode of Delivery in Women with Valvular Heart Diseases *645*; Take Home Message in Valvular Heart Disease Complicating Pregnancy *645*

Section 8: Interventional Cardiology

98. Robotic-assisted PCI 649
Praveen Chandra, Niraj Gupta, Punit Sharma
Clinical Trials *649*; Robotic PCI: A Learning Curve? *652*; Improving Patient Outcomes *652*

99. Intracoronary Assessment to Improve the Outcomes of Coronary Interventions: Role of Optical Coherence Tomography 654
Pratap Chandra Rath, Byomakesh Dikshit, Amit A Bharadiya
Application of Optical Coherence Tomography in Percutaneous Coronary Intervention *655*; Optical Coherence Tomography Follow-up Examinations after Percutaneous Coronary Intervention *658*; Future Directions *658*

100. Intracoronary Assessment to Improve the Outcomes of Coronary Interventions: Role of IVUS 661
G Sengottuvelu, R Ravindran, Dattagupta Aditi
Limitations of Coronary Angiogram *661*; IVUS Evolution *661*; IVUS Technique *662*; Evidence for IVUS Use in PCI *667*; Recommendations for IVUS *667*; Limitations of IVUS *668*

101. Intracoronary Assessment to Improve the Outcomes of Coronary Interventions: Role of Fractional Flow Reserve 669
Brian Pinto, Abhishek Chandorkar
Coronary Circulation *669*; Physiological Indices of the Coronary Circulation *669*

102. Percutaneous Valve Replacement: Expanding Horizons 676
Ashok Seth, Vijay Kumar
What is Percutaneous Heart Valve Replacement *676*; Rationale for Percutaneous Valve Replacement *676*; Different Access Routes to the Heart *676*; Percutaneous Valve Replacement—Its Status Today *676*; Valve in Valve Therapy *682*; Percutaneous Mitral Valve Therapy (Repair and Replacement) *682*

103. Renal Denervation: Still Alive 693
Amal Kumar Banerjee
Symplicity HTN-3: Recent Learning *694*; Prague-15: Important Insights *694*; Rapid Study *694*; Reduce-HTN Clinical Study *695*; Present Scenario *695*

104. Advances in Stent Design 697
K Sarat Chandra, S Nagendra Boopathy
Stents in BMS ERA *697*; Drug-Eluting Stents *697*; Advances in Polymer Technology and Stent Platforms *698*; Biovascular Scaffolds *700*; Self-expanding Stents *700*; Dedicated Bifurcation Stent Systems *701*

105. Management Techniques in Chronic Total Occlusion: Ten Commandments to CTO Intervention 703
Pravin K Goel
Why to Treat CTO *703*; When to Treat CTO *703*; Understanding the CTO Pathology *703*; Imaging for CTO Lesions *704*; Route of Access and Guiding Catheter Selection *704*; Understanding CTO Wires *705*; Wiring Techniques: Antegrade Approach *705*; Wiring Techniques: Retrograde Approach *707*; "Wire Crossed Balloon Not Crossed"—What Next? *709*; Complications of CTO PCI and When Not to do CTO *709*

106. IMA and Vein Graft Interventions: Current Perspective and Future Directions 712
Harinder K Bali, Hiteshi KC Chauhan
Graft Failure *712*; When to Revascularize a Diseased Graft? *713*; Noninvasive Testing *713*; Saphenous Vein Graft Interventions *714*; Stent Type *714*; Intervention Technique *716*; Embolic Protection Devices *716*; Adjuvant Pharmacotherapy *718*

107. Unprotected Left Main Coronary Artery Stenting: Current Status 723
Mathew Samuel Kalarickal, Vijayakumar S
LMCA Anatomy and Pathophysiology Relevant to Percutaneous Coronary Intervention *723*; Risk Stratification for LMCA Revascularization *724*; SYNTAX Score II *724*; Heart Team Approach *724*; Preprocedural Assessment *724*; ULMCA Stenting Techniques: Tips and Tricks *726*; FFR and IVUS Assessment

Poststenting *728*; Syntax Trial *729*; Precombat Study *729*; Florence Registry *730*; ISAR Left Main I and II *730*; Delta Registry *730*; MITO Registry *730*; French Left Main Taxus (FLM Taxus) and the Left Main XIence (LEMAX) Registries *731*; Single versus Two Stent Strategy for Distal ULMCA Disease *731*; Which Two Stent Strategy? *731*; Excel and Noble Trials *731*; Impact of IVUS-guided ULMCA PCI *732*; Antiplatelet Therapy *732*; Follow-up Angiography *732*; Current Guideline Recommendations *732*; Current Understanding of ULMCA PCI: Summary *732*

108. Treatment of Coronary Bifurcation Stenosis **736**
Shuvanan Ray, Sabyasachi Mitra
Stenting MV—The Default Strategy *737*; Dedicated Bifurcation Stents *737*

109. Management of In-stent Restenosis **740**
DS Gambhir
Role of Imaging Modalities *740*; Treatment Strategies for in-stent Restenosis *740*; Conventional Balloon Angioplasty *740*; Cutting Balloon Therapy *740*; Repeat Stenting for in-stent Restenosis *741*; Role of Drug-coated Balloon *741*

110. Ostial Lesions: Tips and Tricks **744**
AB Mehta, Nihar Mehta, Nilesh Tawade
Anatomy of the Ostium *744*; Diagnosis of Aorto-ostial Lesions *744*; Treatment of Ostial Lesions *745*; Choice of Hardware *745*; Lesion Preparation *747*; Stent Positioning *748*; How to Overcome the Problems of Stent Positioning *748*; Poststenting Issues *750*; Unique Complications of Ostial Stenting *750*; Prevention of Complications *751*

111. Role of Distal Embolic Protection Devices in Vascular Intervention **753**
Ashish Amladi, Anil Kumar
Scope of EPD in Various Interventions *754*; EPD in Other Interventions *754*; Embolic Protection: The Devices and their Mechanism of Action *755*

112. Carotid Artery Stenting **759**
Atul Mathur, Amit Kumar
Pathology and Pathophysiology 759; Natural History and Risk Stratification *759*; Anatomy *759*; Clinical Assessment *759*; Noninvasive Testing *759*; Decision Making in Carotid Revascularization *760*; Postprocedural Management *764*; Potential Complications *764*

113. Primary PCI: Tips and Tricks **767**
Gurpreet S Wander, Abhishek Goyal
Time Sensitive Revascularization *767*; Antiplatelet Drugs, Which to Choose *768*; Choice of Anticoagulant: Bivalirudin versus Unfractionated Heparin *769*; Role of Glycoprotein IIB/IIIA Inhibitors *769*; Technical Aspects *769*

114. LV Assist Devices in High-risk Intervention **774**
Sundeep Mishra
Mechanism of Destabilization *774*; High-risk PCI *775*; Cardiac Assist Devices *776*; IABP *776*; ECMO *779*

115. Ulnar Artery Interventions: Tips and Tricks of Transulnar Interventions and Current Perspectives **780**
RK Gokhroor
Arterial Supply of Hand *780*; Need of Ulnar Artery to Strengthen Forearm Access *781*; Tips and Tricks of Ulnar Artery Cannulation *782*; Cannulation of Ulnar Artery *783*; Technique of Ulnar Artery Puncture *785*; Spasmolytic (Cocktail) Therapy *787*; Introduction of Guidewire *787*; Introduction of Introducer Sheath *787*; Learning Curve of Ulnar Artery Cannulation *787*; Experience at Our Center *790*; Factors Predicting Failure of Ulnar Artery Cannulation *791*; Complications *793*; Limitations *793*

116. Stent Thrombosis **795**
Nagendra S Chouhan
Definition of Stent Thrombosis *795*; Pathogenesis of Stent Thrombosis *796*; Stent Malapposition *797*; Endothelial and Neointimal Regeneration and Neoatherosclerosis *798*; Clinical Implications of Stent Thrombosis *799*; Incidence of Stent Thrombosis *800*; Management of Stent Thrombosis *800*

117. Radiation Issues in Cath Lab **804**
Dharmendra Jain, G Subramanian, Balaji lohiya, Niraj Kumar, B Sihag, R Prajapati
Radiation Biology and Health Risks *804*; Assessment of Patient Dose *805*; Assessment of Operator or Lab Personnel Exposure *805*; Concepts of Radiation Protection *805*; Special Considerations *806*

118. Drug-eluting Balloon: Present Scenario **808**
Dilip Kumar, Rana Rathor Roy, Sunip Banerjee, J Naik
Clinical Studies *808*; Drug-eluting Balloon in Bifurcation Lesion *809*; DEB + BMS in De Novo Coronary Lesions *809*; DCB + BMS in Diabetes Mellitus *809*; Drug-eluting Balloon in Peripheral Arteries *810*

Volume 2

Section 9: Cardiomyopathy

119. New Classification of Cardiomyopathies and its Implications **813**
Lekha A Pathak, Mehul Patel, Ronak Ruparelia
Classification *814*; Hypertrophic Cardiomyopathy *815*; Restrictive Cardiomyopathy *815*; Dilated Cardiomyopathy *816*; Arrhythmogenic Right Ventricular Dysplasia *817*; The Impact of Genetic and Genomic Approaches on Current and Future Clinical Application *818*

120. Reversible Cardiomyopathy **821**
Devanu Ghosh Roy
Endocrine Disorders *821*; Toxins and Drugs *821*; Obesity Cardiomyopathy *822*; End-stage Renal Disease Cardiomyopathy *822*; Cirrhotic Cardiomyopathy *822*; Tachycardia-induced Cardiomyopathy *822*; Stress-induced Cardiomyopathy *823*

121. Genetics of Cardiomyopathy **825**
G Justin Paul, P Anandaraj, G Ashok
Classification of Genetic Cardiomyopathies *825*; Genetics of Dilated Cardiomyopathy *826*; Genetics of Hypertrophic Cardiomyopathy *827*; Genetics of Arrhythmogenic Cardiomyopathy *829*; Genetics of Restrictive Cardiomyopathy *830*

122. Noncompaction Cardiomyopathy **832**
VK Katyal
Embryology and Development *833*; Noncompaction of the Myocardium: Congenital or Acquired? *833*; Genetics of Noncompaction of the Left Ventricular Myocardium *833*; Noncompaction: A Distinct Cardiomyopathy? *834*; Histology *834*; Clinical Features, Pathophysiology and Outcome *834*; Diagnosis *835*; Management *837*

123. Cardiomyopathy and Myocarditis in Children **840**
Biswajit Bandopadhyay, Prabhat Kumar
Classification *840*; Epidemiology *841*; Dilated Cardiomyopathy *841*; Hypertrophic Cardiomyopathy *843*; Restrictive Cardiomyopathy *844*; Myocarditis *844*

124. Takotsubo Cardiomyopathy **846**
Suvro Banerjee, Spandan Bhadury
Presentation *846*; Variants *846*; Echocardiography *846*; Electrocardiography *846*; Other Imaging Studies *847*; Endomyocardial Biopsy *847*; Biochemical Changes *847*; Mechanism *847*; Diagnosis *847*; Clinical Outcome and Prognosis *847*; Treatment *847*

125. Hypertrophic Cardiomyopathy: Diagnosis and Management **849**
DP Sinha, Sumanta Mukherjee
Diagnosis *849*; Investigation *849*; Echocardiography *849*; Imaging *850*; Coronary Angiography *852*; Serum Tests *852*; Genetic Counseling and Screening *852*; Treatment *853*; Septal Reduction Therapy *855*; Dual Chamber Pacing *856*; Symptomatic Patients without LVOT *856*; Sudden Cardiac Death Risk Stratification *857*; Atrial Fibrillation *859*; Pregnancy *859*

126. Granulomatous Disease of the Heart **861**
SS Chatterjee, Arka Chatterjee
Granulomatous Lesions of Myocardium *861*; Myocardial Tuberculosis *861*; Cardiac Sarcoidosis *863*

127. Arrhythmogenic Right Ventricular Dysplasia: Assessment and Management **869**
KK Sethi, SK Chuttani
Pathophysiology *869*; Family History and Genetics *871*; Epidemiology *871*; Clinical Presentation *871*; Differential Diagnosis *871*; Natural History of Disease *872*; Assessment and Diagnosis *872*; Therapeutic Recommendations *873*; Prognosis *876*

Section 10: General Cardiology

128. Lifestyle Approach to CVD Prevention **881**
Geevar Zachariah, Deepak Nandan
Evidence for Beneficial Effects of Lifestyle Changes *881*

129. Constrictive Pericarditis vis-a-vis Restrictive Cardiomyopathy: A Judicious Approach **890**
Jabir A, Sajan Ahmad Z, Roney Mathew
Pathophysiology *890*; History *892*; General Examination *892*

130. Dynamic Auscultation: Cardiac and Vascular **898**
V Dayasagar Rao, Shabarinath S
Aims *898*; Types of Bedside Maneuvers *898*; Postural/Positional Changes *898*; Hemodynamics of Respiration *899*; Isometric Exercises *900*; Valsalva Maneuver *900*; Müller's Maneuver *901*; Dynamic Vascular Auscultation *902*

131. Jugular Venous Pulse Demystified **905**
Sankar Paul Chowdhury, Amitava Misra, Kaushik Hazra
What is JVP? *905*; Internal Jugular Vein versus External Jugular Vein (EJV) *905*; Estimation of JVP Beyond Central Venous Pressure *905*; Echo Correlation of Increased PCWP with Jugular Venous Pressure *905*; Body Position and External Reference Point *906*; IJV versus Carotid Pulsation *906*; Effects of Respiration on JVP *908*; RV Diastolic Pressure in Relation to Jugular Venous Pressure *908*

132. Evaluation of a Patient with Syncope due to Cardiovascular Cause **910**
Dipankar Ghosh Dastidar, Nandita Ghosh Dastidar, Narayan Sarkar
Epidemiology *910*; Genetic Predisposition *911*; Prognosis *911*; Recent Updates *911*; Classification *911*; Initial Evaluation *912*; Distinguishing Syncope from Seizures *912*; Establishing Diagnosis of Vasovagal Syncope *912*; Risk Stratification *913*; Diagnostic Tests *915*; Orthostatic Challenge *915*; Prolonged ECG Monitoring *915*; Treatment *920*; Improvements in Management of Syncope *922*

Section 11: Pediatric Cardiology

133. Clinical Approach to Congenital Cyanotic Heart Disease **929**
Anita Saxena
Approach to a Patient with Cyanotic Congenital Heart Disease *929*; Confirming the Diagnosis *932*

134. Diagnosis and Management of Congenital Heart Disease in Adults **935**
R Krishna Kumar
Congenital Cardiac Conditions are Encountered in Adults *935*; Other Investigative Tools and their Optimal use *941*

135. ECG Interpretation in Congenital Heart Disease **942**
Maitri Choudhri
Anatomy of the Conduction System in CHD *942*; Bedside use of ECG in CHD *942*

136. Timing of Intervention in Congenital Heart Disease **957**
Manisha Chakrabarti
Post-tricuspid Shunts *958*; Obstructive Lesions *959*; Cyanotic Congenital Heart Disease *960*; Outcome *961*

137. Fontan Surgery Evolution **963**
Kaushik Mukherjee, Plaban Mukherjee
Selection of Patients *963*; Surgical Evolution *964*; Future Prospect *966*

138. A Systematic Approach to Grown-up Congenital Heart Disease **968**
Bhanu Duggal, Kaushik Patil, Pankaj Raut
Shunt Lesions *968*; Obstructive Lesions *969*; Complex Congenital Heart Disease *972*;
Ebstein's Anomaly of the Tricuspid Valve (No Right Ventricular Hypertrophy) *973*;
Patients with Prior Surgery in Childhood *974*; D-transposition of Great Arteries *974*

139. Operability Assessment in Left-to-Right Shunt with Pulmonary Hypertension **975**
Bharat Dalvi, Kshitij Sheth
Pathogenesis of Pulmonary Vascular Disease *975*; Reversible versus Irreversible Pulmonary Hypertension *976*;
Determining Operability *976*; Special Conditions *979*

140. Eisenmenger Syndrome: An Update **981**
Jaganmohan Tharakan, Subramanian Venkateshwaran
Epidemiology *981*; Pathogenesis *982*; Pathophysiology of Eisenmenger Syndrome *983*; Clinical Features *985*;
Investigations *985*; Treatment *986*; Prognosis *988*; Future Prospects *989*

141. Recent Advances in use of Devices and Stents in Pediatric Cardiac Catheter Interventions **991**
S Radhakrishnan, Neeraj Awasthy, Manisha Chakrabarti
Advances in Use of Devices in Pediatric Cardiac Care *991*; Occlusion of the Vessel *994*

142. Transposition Physiology **1001**
Balachander Jayaraman, Mahesh Kumar S
Morphological Considerations *1001*; TGA Physiology *1002*; Fetal Circulation *1002*; TGA with Inadequate
Pulmonary-systemic Communication *1005*

143. Chest X-ray Abnormality in Congenital Heart Disease: An Approach **1012**
Shyam S Kothari
Common Errors *1015*

144. Syndromes Associated with Congenital Heart Diseases **1019**
Mrutyunjoy Satpathy
Aneuploidy Syndromes *1019*

Section 12: Electrophysiology and Arrhythmia

145. Basics of Electrophysiological Studies **1027**
G Karthikeyan
Indications *1027*; Equipment and Setting *1029*; Techniques and Procedures *1029*; Atrial Stimulation *1030*;
Ventricular Stimulation *1031*; Use of Cardioactive Drugs During EPSs *1031*

146. Basics of Radiofrequency Ablation **1033**
Aftab Khan
Cooled-tip Radiofrequency Ablation *1033*; Radiofrequency Catheter Ablation of Accessory Pathways *1033*; Radiofrequency Catheter Modification of the AV Node for AV Nodal Re-enrtrant Tachycardias *1034*; Radiofrequency Catheter Ablation of Atrial Tachycardia *1035*; Radiofrequency Catheter Ablation of Atrial Flutter *1035*; Radiofrequency Catheter Ablation of Atrial Fibrillation *1036*; Radiofrequency Catheter Ablation of Ventricular Tachycardia *1036*; New Mapping and Ablation Technologies *1037*

147. Inherited Arrhythmia Syndromes **1038**
Md Azizul Haque
Inherited Arrhythmia Syndromes *1038*; Brugada Syndrome *1038*; Long QT Syndrome *1040*; Short QT Syndrome *1041*; Catecholaminergic Polymorphic Ventricular Tachycardia *1042*; ECG *1042*; Early Repolarization Syndrome *1042*; Idiopathic Ventricular Fibrillation *1042*; Progressive Cardiac Conduction System Disease *1043*

148. ICD Troubleshooting **1044**
Yash Lokhandwala, Aniruddha Vyas
A Short Series of Problems *1044*; Troubleshooting an ICD *1047*

149. Tachycardiomyopathy **1054**
Rajat Mohan, Kavita Tyagi
Incidence and Predisposing Factors *1055*; Pathophysiology *1055*; Clinical Diagnosis *1055*; Echocardiographic Indexes *1056*; Asynchrony *1056*; Premature Ventricular Complexes *1057*; Treatment *1057*; Follow-up and Risk of Recurrence *1058*; Prognosis *1058*

150. Ablation of Ventricular Tachycardia **1060**
C Narasimhan, Anees Thajudeen
Ablation of Idiopathic Ventricular Tachycardia *1060*; Methods of Ablation of Ventricular Tachycardia *1063*; Results of Ventricular Tachycardia Ablation *1065*; Future of Ventricular Tachycardia Ablation—Applying Newer Technologies *1066*

151. Recent Innovations in Pacemaker Technology **1068**
Balbir Singh
Avoidance of Unnecessary Right Ventricular Stimulation *1068*; Leadless Pacemaker *1070*; Batteryless Pacemaker *1071*

152. New Mapping Technologies **1072**
Mohan Nair
Current Electroanatomical Cardiac Mapping System Technologies *1072*; New Mapping and Navigation Systems *1075*; Feature Updates for Carto 3 and Ensite Velocity Systems *1077*; New Alternative Mapping Technologies *1078*

153. Atrial Fibrillation Ablation: A Primer **1080**
Amit Vora, Mate Swapnil Dhondibhau
Pathophysiology of Atrial Fibrillation *1080*

154. Autonomic Modulation for Control of Arrhythmias **1086**
Ulhas M Pandurangi, Anitha G PA
Autonomic Tone in Cardiac Arrhythmias *1086*; Atrial Fibrillation *1087*; Ventricular Tachyarrhythmias *1089*

155. WATCHMAN Device: Implantation Techniques and Current Use **1093**
Brajesh Mittal
Percutaneous Approaches to Occlude the Left Atrial Appendage *1094*; Current Indication of WATCHMAN Device *1094*; Preprocedure Transesophageal Echocardiography *1095*; Patient Preparation and Material *1095*; Device Implantation Technique *1095*; Implant Recapture *1097*; Postprocedure Management *1097*

156. Pacemaker Infection **1099**
A Ganguly
Classification *1099*; Epidemiology *1100*; Microbiology *1100*; Clinical Presentation *1101*; Diagnosis *1101*; Prevention *1102*; Treatment *1104*

157. Sports and Arrhythmia: Recent Insights of the Pathophysiology **1112**
Bhabani Prasad Chattopadhyay, Rammohan Roy, Supratip Kundu, Bappaditya Kumar
Epidemiology and Etiology of Sudden Cardiac Death and Related Cardiac Arrhythmias *1112*; Pathophysiology of Sports-related Cardiac Arrhythmias *1112*; Mechanisms of Atrial Fibrillation and Flutter in Sports *1113*

158. Atrial Fibrillation and Stroke Prevention **1115**
Satyendra Tewari, Deep Chandh Raja S
Risk Stratification in Patients of Nonvalvular AF *1115*; Tools for Risk Stratification of Nonvalvular AF for Stroke Risk *1116*; Tools for Risk Assessment of Bleeding Risk *1116*; Biomarkers may Predict Risk of Stroke *1116*; Rationale for Anticoagulation *1116*; Newer Oral Anticoagulants *1117*; Management of Bleeding with NOACs *1118*; Mechanical Interventions for Stroke Prevention in AF *1118*

159. Subcutaneous ICD: Is it the Future? **1121**
Oruganti Sai Satish
Overview of Subcutaneous ICD Technology *1121*; S-ICD Implantation *1122*; Future Directions *1125*

Section 13: Pericardial Disease

160. Pathology of Pericardial Disease and the Hemodynamic Alteration **1129**
Sibananda Dutta, Soumik Chaudhuri, Sreedhara R
Normal Pericardium *1129*; Physiology of the Pericardium *1129*; Constrictive Pericarditis *1129*; Variants of Constrictive Pericarditis *1130*; Features Useful in Differentiating Constrictive Pericarditis from Restrictive Cardiomyopathy *1133*; Cardiac Tamponade *1134*; Hemodynamic Spectrum of Cardiac Tamponade *1135*; Intracardiac Pressure Curves *1137*; Treatment *1137*

Section 14: Cardiac Malignancies

161. Cardiac Tumors **1143**
Chandan Misra, Md Miraj Mondal
Clinical Presentation *1143*; Primary Malignant Tumors *1145*; Diagnosis *1145*

Section 15: Pulmonary Disease

162. Pulmonary Arterial Hypertension: Newer Developments **1149**
S Harikrishnan
Pathogenesis *1149*; Advances in Therapy *1149*; Combination Therapy *1151*

163. Pulmonary Embolism: Assessment and Management **1154**
Rajesh K Agrawal
Assessment *1154*; Clinical Probability Assessment *1155*; Management *1156*

Section 16: Infections, Toxins and Drugs

164. Cardiovascular Diseases in HIV-infected Individuals **1163**
Biswakesh Majumdar, Durga Prasad Rai
Risk of Cardiovascular Disease in HIV-infected Persons *1163*; HIV-related Factors *1163*; Antiretroviral Therapy-related Factors *1164*; Accelerated Atherosclerosis *1164*; Left Ventricular Systolic Dysfunction *1164*; Pulmonary Hypertension *1165*; Pericardial Effusion *1165*; Infective Endocarditis *1166*; Nonbacterial Thrombotic Endocarditis *1166*; Cardiovascular Malignancy *1166*; Autonomic Dysfunction *1166*; Long QT Interval *1167*

165. Heart and Environmental Pollution **1168**
Vitull K Gupta, Varun Gupta, Meghna Gupta
Air Pollution *1168*; Water Pollutions *1169*; Noise Pollution *1169*; Soil Pollution *1169*; Light Pollution *1169*; Heart and Environmental Pollution *1169*; Biologic Mechanisms *1170*; Air Pollution and Cardiovascular Disease *1170*

166. Cardiotoxic Drugs and their Monitoring **1176**
Mriganka S Chaliha
Definition of Cardiotoxicity *1177*; Definition of Chemotherapy-induced Heart Failure *1177*; Clinical Spectrum of Cardiotoxicity *1177*; Different Chemotherapeutic Agents and Cardiotoxicity *1178*; Cardiotoxicity Due to Other Myocardial Toxins *1179*; Mechanism of Cardiotoxicity Due to Chemotherapeutic Agents *1180*; Monitoring *1180*; Guideline-based Monitoring for Specific Agents and Algorithms for Monitoring Cardiotoxicity *1183*

Section 17: Miscellaneous

167. Obesity and Heart Disease **1189**
Sourangsu Chatterjee
Prevalence *1189*; Measurement of Obesity *1189*; Classification of Adults According to BMI (WHO 2003) *1190*; Pathophysiology *1190*; Effect of Obesity on Cardiac Performance *1190*; Effects of Obesity on Hemodynamics and Cardiovascular Structure and Function *1191*; Heart Failure *1191*; Arrhythmias *1192*; Coronary Artery Disease *1192*; Obesity Paradox *1192*; Interpretation of Investigations in the Obese Patients *1193*

168. Obstructive Sleep Apnea: Impacts on Cardiovascular System **1196**
Manoranjan Mandal, Dhua Debargha
Mechanism of Obstructive Sleep Apnea *1196*; Screening *1197*; Diagnosis *1197*; Mechanism *1197*; Cardiovascular Diseases and Obstructive Sleep Apnea *1199*; Treatment Options in Obstructive Sleep Apnea *1205*

169. Mental Disorders and Cardiovascular Diseases **1208**
Ratan Kumar Kotokey, Avisek Chakravorty
Stress and Cardiovascular Diseases *1208*; Major Depression/Dysthymia and Cardiovascular Diseases *1209*; Psychological Disorders and Cardiovascular Diseases in the Light of Yoga *1210*

170. Current Status of Management of Takayasu Arteritis **1213**
Manotosh Panja, Madhumanti Panja
Clinical Features *1214*; CT/MRA *1215*; US *1215*; Management *1215*; Prognosis *1219*

171. Yoga in Cardiovascular Disease Prevention **1220**
SC Manchanda, Kushal Madan
Yoga for Control of Risk Factors *1220*

172. Cardiac Involvement in Oncotherapy **1225**
Shishu Shankar Mishra, Biswaranjan Mishra, SN Routray, TK Mishra, PK Pradhan
Cardio-Oncology/Onco-Cardiology *1225*; Definition of Cardiotoxicity *1225*; Incidence of Cardiotoxicity *1226*; Types of Cardiac involvement *1226*; Chemotherapeutic Agents Implicated in Cardiotoxicity *1226*; Pathophysiology of Cardiotoxicity *1227*; Assessment of Cardiotoxicity *1227*; Protection from Cardiotoxicity *1228*

173. Telecardiology **1231**
Sunita Maheshwari
Burden of Disease *1231*; Where are the Cardiologists? *1231*; Telecardiology: A Solution *1231*

174. Metabolic Syndrome: An Overview **1235**
DJ Dutta, RMW Bora
Evolution of Diagnostic Criteria *1235*; Epidemiology *1236*; Cardiovascular Risk in Metabolic Syndrome *1237*; Pathophysiology *1238*; Central/Abdominal Obesity *1238*; Hypertension in Metabolic Syndrome *1238*; Dyslipidemia In Metabolic Syndrome *1238*; Management of Metabolic Syndrome *1239*; Diet and Lifestyle Modification *1239*; Physical Activity *1240*; Drug Therapy *1240*

175. MRI and Cardiac Devices **1243**
Charan Pandurang Lanjewar, Patil Devendra V
Technical Considerations *1243*; Effects of MRI on Implanted Devices *1243*; Terminologies Regarding Labeling *1244*; MRI and Different Cardiac Devices *1244*; Approach to Patient with Cardiac Device being Planned for MRI *1248*

176. Monoclonal Antibodies in Cardiovascular Therapeutics **1251**
Asha Moorthy, Jain T Kallarakkal

177. Smoking and Cardiovascular Disease: The Key Issues **1253**
Sandeep Gupta, Barron Sin, Shrutti Dhar
Prevalence of Tobacco Smoking *1253*; Management of Smoking Cessation *1257*

178. Selection of Edible Oil: How Important in CVD Prevention **1262**
Pradeep Kumar Gupta, Debdatta Bhattacharya, Peeyoosh Rai
Fats and Oils *1262*; Fats: Classification *1263*; Edible Oil Industry: Indian Perspective *1264*; Edible Oils: Indian Cooking Conditions *1264*; Predimed Trial *1265*; Vegetable Oils *1265*

Section 18: Echocardiography

179. LV Strain: Ready for Prime Time **1271**
Shantanu P Sengupta
Technical Consideration *1271*; How to Obtain Strain Parameters *1273*; Clinical Applications *1273*; 3D Speckle Tracking Imaging *1276*; Differences Between 2D- and 3D-Derived-STE Clinical Data *1276*; Limitations *1276*

180. Echo Imaging in Cancer Chemotherapy: Recent Updates **1278**
Manish Bansal, Ravi R Kasliwal
Cardiotoxicity with Cancer Chemotherapeutic Agents *1278*; Role of Echocardiographic Imaging in Patients Receiving Cancer Chemotherapy *1280*; Role of Stress Echocardiography *1284*; Echocardiographic Imaging Protocol in Patients Receiving Cancer Chemotherapy *1284*

181. Echo in Mitral Stenosis: Redefined **1287**
Nitin J Burkule
Practical Echocardiographic Observations *1287*; Applications of 3D Echocardiography *1288*; Predicting AF and Thromboembolism *1290*; Concept of Net Atrioventricular Compliance (Cn) *1290*; Determinants of Exercise Capacity and Pulmonary Hypertension (PH) in MS *1291*; LV Dysfunction in MS *1292*; RV Function Recovery and Progression of Tricuspid Regurgitation (TR) after BMV *1292*; Echo Guidance During BMV *1292*

182. Constriction Versus Restriction: An Echocardiographic Approach **1294**
Biswajit Majumder, Sougat Chakraborty, Viral Tandel
M-Mode and 2D Echocardiographic Findings *1294*; Doppler Findings *1294*; Speckle Tracking and Strain Imaging *1297*

183. Left Ventricular Functions in Aortic Stenosis **1298**
Satish K Parashar
Concept of LV Function and Myocardial Fibers *1298*; Pathophysiology of Aortic Stenosis and Longitudinal LV Function *1299*; Significance of LV Function in as Management *1300*; Deformation Imaging *1301*; Detection of Subclinical Myocardial Dysfunction *1301*; Impact of LV Functions in Evaluation and Management of Aortic Stenosis *1301*

184. Three-dimensional Echocardiography: Current Status and Clinical Usefulness **1304**
HK Chopra, Gautam Reddy, Mahmoud Elsayed, Saima H Khan, Naga Sai Shravan Turaga, Arunbabu Sankaranarayanan, Navin C Nanda
Global Ventricular Function *1304*; Regional Ventricular Function *1306*; Speckle Tracking and Area Strain *1306*; Primary Myocardial Disorders *1307*; Valvular Heart Disease *1308*; Prosthetic Cardiac Valves *1311*; Congenital Heart Disease *1313*; Intracardiac Masses *1314*; Interventional Procedures *1315*

185. Intracardiac Flow Vortex Imaging **1321**
Ravi R Kasliwal, Manish Bansal
How these Vortices Form? *1321*; Visualization and Quantification of Intracardiac Flow Patterns *1321*; Significance in Health and Disease States *1325*

186. Myocardial Contrast Echocardiography **1329**
Rakesh Gupta, Parth Sthapak
Assessment of Myocardial Perfusion *1329*; Left Ventricular Opacification *1331*; Myocardial Perfusion Imaging *1332*; Safety *1335*; Practical Issues *1336*; Future *1336*

187. Echocardiographic Assessment of Prosthetic Valve **1339**
Jacob V Jose, Nisha Jose
Evaluation of Prosthetic Valves *1339*; Prosthetic Mitral Valve *1339*; Prosthetic Aortic Valve—Aortic Valve Replacement (AVR) *1340*; Differentiation of Thrombus from Pannus *1344*; Patient Prosthesis Mismatch *1344*; Infective Endocarditis *1345*

188. Chamber Quantification by Echocardiography: Recent Update **1346**
Debika Chatterjee
Left Ventricle *1346*; Right Ventricle *1348*; Left Atrium *1349*; Right Atrium *1350*; Aorta *1350*; Inferior Vena Cava *1351*

189. Diastology **1353**
Aniruddha De
What is Diastole? *1353*; Transmitral Doppler Inflow *1353*; Isovolumic Relaxation Time *1354*; Tissue Doppler Imaging *1355*; Pulmonary Venous Doppler Flow *1356*; Mitral Inflow Propagation Velocity *1356* Diastolic Stress Test *1357*; Grades of Diastolic Dysfuncion *1357*; Diastolic Function in Atrial Fibrillation *1357*

Diastolic Function in Constriction *1357*; Left Atrial Volume *1357*; New Diastolic Indices and their Clinical Applications *1358*; Ventricular Strain, Strain Rate and Twist *1358;* Assessment of LV Global Diastolic Function *1358*; Clinical Utility of Diastolic Dysfunction *1360*

190. Echocardiographic Assessment of Right Ventricular Function **1363**
Dipankar Datta
Assessment of RV Systolic Function *1363*; Assessment of RV Diastolic Function *1368*

191. Expanding Spectrum of Stress Echocardiography **1370**
Abhijit Chatterjee
Critical Appraisal of the Current Methodology *1370*; Myocardial Viability Study *1371*; Valvular Heart Disease *1372*; Cardiomyopathy *1373*; Estimation of Coronary Artery Blood Flow *1373*

192. Role of Echocardiography in Cardiac Resynchronization Therapy in Predicting Response and Optimizing the Efficacy **1374**
S Shanmugasundaram, B Vinodkumar, U Ilayaraja
Indications for Biventricular Pacing *1374*; Rationale *1374*; Electrical and Mechanical Dyssynchrony are not Always Inter-related *1375*; The Potential Utility of Echo in CRT *1375*; Does Echo Predict who will Respond? *1376*; Methodology *1377*; Intraventricular Dyssynchrony *1377*; Atrioventricular Dyssynchrony *1382*; Interventricular Dyssynchrony *1383*; Echo to Guide Lead Placement *1383*; Echo for Follow-up after CRT Implant *1384*; Echo for Optimization of CRT *1384*; How to go About: The Practicalities *1385*

193. Real-time Three-dimensional Echocardiography for Guidance of Noncoronary Interventions **1388**
R Alagesan, Satish C Govind
Echocardiography in Paravalvular Regurgitation *1388*; Echocardiography in Mitral Valve Clip Procedure *1389*; Echocardiography in Transcatheter Aortic Valve Implantation *1392*; Echocardiography in Atrial Septal Defect Closure *1394*; Echocardiography in Percutaneous Transmitral Commissurotomy *1395*

Section 19: Biostatistics and Genetics

194. Medical Statistics: What Every Doctor should Know? **1401**
Tiny Nair
Probability: (P) *1401*; Odds and Odds Ratio *1401*; Risk and Risk Ratio *1402*; Standard Deviation *1402*; How to use SD Intelligently *1402*; Confidence Interval *1402*; Study Example: How to Interpret a Clinical Trial *1403*

195. Pharmacogenomics: Current and Future **1405**
Rakesh Yadav
Use of Pharmacogenomics in Field of Cardiovascular Medicine *1406*; Challenges in Pharmacogenomics *1406*

196. Micro-RNA-based Diagnosis and Therapy in Cardiology: Promising Times Ahead **1408**
Arnab Dutta, Imran Ahmed
Genetics of Micro-RNA *1408*; Micro-RNAs in Myocardial Development and Disease *1408*; Micro-RNAs in Vascular Diseases *1408*

197. Nanotechnology for Diagnosis and Treatment of Cardiovascular Diseases **1411**
Madhab Ray, Santanu Guha
Basics about the Nanoparticles *1411*; Collagen-targeted Paramagnetic Micellar Nanoparticle *1411*; Characteristics of Nanoparticles *1411*; Nanotechnology for Diagnosis of Cardiovascular Diseases *1411*; Nanotechnology for Treatment of Cardiovascular Diseases *1413*; Toxicities and Adverse Effects *1414* Current State and Future Directions *1414*

Section 20: Stem Cell

198. Application of Stem Cell Therapy in Cardiovascular Disease: Current Status **1419**
Arindam Pande
Fundamental Principles *1419*; Mechanism of Action by Which Cell Transplantation Demonstrates Clinical Efficacy *1423*; Approach for Clinical Cardiac Regeneration *1423*; Clinical Applications *1424*; Chronic Ischemic Cardiomyopathy and Heart Failure *1425*; Future Perspectives *1425*

Section 21: Cardiac Surgery

199. Surgical Treatment of Ischemic Mitral Regurgitation **1431**
Anil Jain
Pathophysiology *1431*; Papillary Muscle Dysfunction *1432*; Other Mechanisms of Ischemic Mitral Regurgitation *1432*; Surgical Intervention for Ischemic Mitral Regurgitation *1435*; Surgical Treatment of Ischemic Mitral Regurgitation *1438*; ACC/AHA 2006 Guidelines *1439*; Results of Review of Literature *1440*

200. Scope of Valve Conservation in Aortic Valve Disease **1444**
Padmanabhan Chandrasekar
Anatomy and Pathophysiology of Aortic Root and its Implication on Valve Sparing Surgery *1444*; Role of Echocardiography *1445*; Surgical Considerations in Valve Conservation *1448*; Bicuspid Valve *1448*; Children *1450*; Results and Outcomes *1450*; Comments *1450*

201. Is Off-Pump Coronary Artery Bypass Surgery a Sustainable Method of Coronary Artery Bypass Grafting? **1452**
Kunal Sarkar

202. Functional Tricuspid Regurgitation: Today's Approach **1455**
Plaban Mukherjee, Kaushik Mukherjee
Pathogenesis of Functional Tricuspid Regurgitation *1455*; Assessment of Functional Tricuspid Regurgitation *1457*; Therapeutic Decision Making *1458*; Surgical Options *1458*; New Directions in Tricuspid Valve Repair *1459*

203. Heart and Heart-lung Transplantation: Indian Scenario **1460**
T Sunder, T Paul Ramesh, K Madhan Kumar
Brief Historical Aspects *1460*; Indications *1460*; Natural History of the Heart Failure and Timing of Transplant Surgery: "The Transplant Window" *1461*; Recipient Selection *1461*; Surgical Aspects *1461*; Immunosuppressive Therapy *1462*; Post-transplant Surveillance Biopsy *1462*; Situations Specific to the Indian Subcontinent *1462*; Centers in India Performing Transplantation *1463*; Our Experience *1463*

Section 22: Diseases of Aorta

204. Acute Aortic Syndrome: Evaluation and Management **1467**
Atanu Saha
Pathophysiology *1467*; Epidemiology *1468*; Classification *1468*; Clinical Features *1468*; Diagnostic Modalities *1469*; Management *1470*

205. Aortic Aneurysms—Management Strategies: A Surgeon's Viewpoint **1472**
Naresh Trehan, Manvendra Singh, Anil Bhan
Thoracic Aortic Aneurysms *1472*; Pathogenesis *1472*; Natural History *1473*; Clinical Presentation *1473*; Physical Examination *1474*; Investigations *1474*; Imaging *1474*; Medical Management *1474*; Thoracic Aneurysm Repair *1474*; Indications *1474*; Preoperative Evaluation *1474*; Perioperative Monitoring *1474*; Open Surgical Repair *1474*; Vascular Control *1475*; Cerebral Protection *1475*; Bicuspid Aortic Valve *1475*; Arch Aneurysms

1475; Abdominal Aortic Aneurysms *1476*; Risk Factors *1476*; Natural History *1476*; Clinical Presentation *1476*; Examination *1476*; Imaging *1477*; AAA Repair *1477*

206. Aortic Aneurysm—Management Strategies: An Interventional Cardiologist's Viewpoint **1478**
George Joseph

Section 23: Imaging

207. PET MRI: The New Frontier in Ischemia and Viability Imaging **1485**
Sangeeta Taneja, A Jena
Pet and MRI for Viability Assessment *1486*; About the Scanner *1486*; Postprocessing and Evaluation *1487*; Discussion and Literature Review *1487*; Contraindications and Limitations *1489*

208. Myocardial Perfusion by Coronary Computed Tomography **1491**
Johann Christopher
Myocardial Perfusion by Conventional Nuclear Techniques *1491*; Study Protocol *1492*

209. HeartFlow FFR_{CT} Analysis for the Noninvasive Diagnosis of CAD **1497**
Ravi Bathina, Christopher K Zarins, Sreenivas K Arramraju
Invasive Fractional Flow Reserve *1497*; Noninvasive Fractional Flow Reserve: HeartFlow FFR_{CT} Analysis *1498*; Clinical Evidence for HeartFlow Analysis *1500*; Clinical use of FFR_{CT} *1501*; Cost Effectiveness Analysis *1501*; Potential Cost Effectiveness in India *1501*

210. Role of PET-CT in the Assessment of Cardiac Disorders **1505**
GN Mahapatra
PET Radiopharmaceuticals for Cardiac Disorders *1505*; Tracers for Myocardial Perfusion *1505*; Tracers for Absolute Quantitation of Myocardial Blood Flow *1507*; Protocol *1509*; Tracers for Myocardial Metabolism *1510*; Tracers for Detecting Chronic Inflammatory Disorders such as Cardiac Sarcoidosis/Amyloidosis *1512*; Tracers for Detecting Atheromatous Plaque Particularly Vulnerable Plaque Imaging *1513*; Tracers for Stem Cells Tracking *1513*; Tracers for Patients with Infectious Endocarditis and Aortic Graft Prosthetic Infection *1513*

211. Myocardial Viability by Multimodality Imaging **1516**
Vimal Raj, Onkar Auti
Echocardiography *1517*; SPECT *1517*; PET-CT *1517*; Cardiac Magnetic Resonance Imaging *1517*; Computed Tomography *1518*; Comparison of Different Imaging Techniques *1518*

212. An Update on Cardiac Magnetic Resonance Imaging in Cardiomyopathy **1520**
Elizabeth Joseph, Aparna Irodi, Binita Chacko, Leena RV, Varsha Kiron
Dilated Cardiomyopathy *1520*; Hypertrophic Cardiomyopathy *1523*; Arrhythmogenic Right Ventricular Dysplasia or Cardiomyopathy *1528*; Restrictive Cardiomyopathy *1529*; Interventions in Cardiomyopathies *1531*

213. Cardiac Magnetic Resonance Imaging in Congenital Heart Disease **1536**
R Rajeshkannan
Technical Aspects *1536*; Anatomical Assessment *1537*; Functional Assessment *1539*; Postoperative Evaluation *1540*; Computed Tomography versus Magnetic Resonance Imaging in Congenital Heart Disease *1541*

Section 24: Peripheral Vascular Disease

214. Renal Artery Stenting: Present Status **1545**
Sanjay Tyagi, Prattay Guha Sarkar, Swati Tyagi
Clinical Impact of Renal Artery Stenosis *1545*; Etiology *1545*; Management of Renal Artery Stenosis *1545*; American College of Cardiology/American Heart Association Guidelines for Screening for Renal Artery Stenosis (Class I) *1546*; Medical Treatment *1546*; When there is Renal Artery Stenosis? *1546*; Technical

Considerations *1547*; Patient Selection for Percutaneous Transluminal Renal Angioplasty *1547*; Clinical Results in Atherosclerotic Renal Artery Stenosis *1548*

215. Management of DVT: Status Report 2015 **1551**
Santhosh Satheesh, Krishna Sarin MS
Diagnosis *1551*; Acute Management of DVT *1552*; Search for an Underlying Etiology *1556*; Long-term Management *1557*

216. Endovascular Management of Varicose Veins **1560**
Shoaib F Padaria
Compression Therapy *1560*; Sclerotherapy *1560*; Surgical Treatment/Surgery for Varicose Veins *1561*; Endovenous Thermal Ablation *1561*; The Indian Experience *1564*

217. Interventions for Male Erectile Dysfunction: Any Role for Cardiologists? **1567**
NN Khanna
Anatomy *1567*; Physiology of Erection *1568*; Diagnosis *1568*; Angiography *1569*;

Index **I–1**